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Abstract
Affective disorders, which include anxiety and depression, are highly prevalent and have overwhelming emotional
and physical symptoms. Despite human brain imaging studies, which have implicated the prefrontal cortex
including the anterior cingulate cortex (ACC), little is known about the ACC in anxiety disorders. Here we show
that the ACC does modulate anxiety-like behavior in adult mice, and have identified a protein that is critical for
this modulation. Absence of neurabin, a cytoskeletal protein, resulted in reduced anxiety-like behavior and
increased depression-like behavior. Selective inhibition of neurabin in the ACC reproduced the anxiety but not the
depression phenotype. Furthermore, loss of neurabin increased the presynaptic release of glutamate and cingulate
neuronal excitability. These findings reveal novel roles of the ACC in anxiety disorders, and provide a new
therapeutic target for the treatment of anxiety disorders.
Introduction
Affective disorders are among the most common psy-
chiatric diagnoses [1]. Selective Serotonin Reuptake
Inhibitors (SSRIs) are the most commonly prescribed
drugs for such mood disorders, but very little is known
regarding the molecular mechanisms and the specific
neural circuits that underlie both the disorders and the
drugs’ effects [2]. Additionally, while treatments for
affective disorders are effective, many patients are left
with residual symptoms or experience side effects that
limit their adherence to prescribed regimens [3].
Although numerous human brain imaging studies have
implicated the prefrontal cortex (PFC) including the
ACC in affective disorders [4-6], the exact role of the
ACC in affective disorders still remains unknown.
Neurabin is a cytoskeletal protein found both in den-
dritic spines and axon terminals [7]. Neurabin interacts
directly with the filamentous actin cytoskeleton [8,9]. In
addition to the actin-binding domain, neurabin contains
several other domains critical for their function, such as
protein phosphatase 1(PP1)-binding motif [10,11]. Pre-
vious studies in the hippocampus have found that
neurabin contributes to the regulation of glutamate
AMPA receptor functions and its related plasticity [12].
Additionally, numerous drugs affecting anxiety affect
AMPA receptor-mediated excitatory transmission in the
PFC [13], and antagonism of AMPA receptors have
been found to reduce anxiety-like behaviors [14,15]. Stu-
dies have also found that synaptic transmission and
plasticity in the ACC is critical for pain, fear, and learn-
ing and memory [16-24], and recently, it was found that
neurons in the ACC form local excitatory and inhibitory
connections [25]. In the ACC, excitatory synaptic trans-
mission is mediated by glutamate and GABA mediates
inhibitory synaptic transmission. As benzodiazepines,
which are clinically used to treat anxiety disorders, pro-
mote binding of GABA to GABAA receptor, these con-
nections in the ACC could be essential in modulating
anxiety-like behaviors.
Here, we demonstrate that the injections of muscimol,
a potent, selective GABAA receptor agonist, as well as
midazolam, a clinically used benzodiazepine, into the
ACC reduced anxiety-like behaviors. Neurabin knockout
(KO) mice had reduced anxiety-like behavior but
increased depression-like behavior. Selective inhibition
of neurabin in the ACC using siRNA reproduced the
anxiety-like behavior phenotype but did not affect the
depression-like behavior. Furthermore, deletion or
reduction of neurabin increased the presynaptic release
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study demonstrates the role of the ACC in affective dis-
orders, and that neurabin may be a possible new thera-
peutic target for the treatment of anxiety disorders.
Materials and methods
Animals
Adult male mice (8-12 weeks old) were used for all
experiments. All mice were maintained on a 12 h light/
dark cycle with food and water provided ad libitum.A l l
protocols used were approved by The Animal Care and
Use Committee at the University of Toronto.
Behavioral tests
Elevated plus maze
The apparatus consisted of two opposing open and
closed arms. For each test, the animal was placed in the
centre square and allowed to move freely for 5 min. The
number of entries and time spent in each arm were
recorded.
Open field
To record horizontal activity, Activity Monitor system
from Med Associates (St. Albans, VT) was used. Briefly,
this system used paired sets of photo beams to detect
movement in the open field and movement was
recorded as beam breaks. The open field was placed
inside an isolation chamber with dim illumination and a
fan. Each subject was placed in the centre of the open
field and activity was measured for 30 minutes.
Light/dark test
The apparatus consisted of a rectangular Plexiglas box
(44 × 8.5 × 25 cm) equally divided into a light and dark
compartment that was separated by a door. Each animal
was placed in the light compartment and was allowed
10 sec to explore, after which the door to the dark com-
partment was opened. The time spent in both compart-
ments was recorded for 10 min.
Elevated emergence task
The apparatus consisted of a rectangular Plexiglas floor
equally divided into opaque and clear sections, with the
opaque section surrounded on three sides by high walls,
resting on an elevated platform, while clear section was
not enclosed and suspended over the floor from the ele-
vated platform. For each test, the animal was placed in
the opaque section and was allowed to move freely for
5 min. The latency to cross into the clear floor and time
spent were recorded.
Forced swim test
Mice were placed in a transparent plastic tub containing
water (23-25°C). Each mouse was tested for 6 minutes.
The mouse was allowed to swim freely for 2 min. Time
spent immobile (aside from small maintenance move-
ments) was recorded during the last 4 minutes. After
the test, the animals were allowed to dry in a heated
cage before being returned to the home cage. The water
was changed after each mouse.
Western blot
Briefly, cultured cortical neurons were harvested and
homogenized in lysis buffer. Electrophoresis of equal
amounts of total protein was run on SDS-polyacrylamide
gels. Separated proteins were transferred to polyvinyli-
dene fluoride membranes overnight at 4°C. Membranes
were probed with primary antibodies against neurabin
(Millipore Corporation, California) and actin (Sigma,
MO) overnight at 4°C. The membranes were then incu-
bated with horseradish peroxidase-coupled secondary
antibody for 2 h at room temperature followed by
enhanced chemiluminescence (ECL) detection using
Western Lightning Chemiluminescence Reagent Plus
(Perkin Elmer Life sciences, MA). The density of immu-
noblots was measured with NIH ImageJ software.
Brain cannulation and microinjection
Mice were anesthetized with i.p. injection of a mixture
of xylazine (10 mg/kg) and ketamine (130 mg/kg). The
fur above the skull was shaved and the skin cleaned
with alcohol, Triadine, then alcohol. The head of the
mouse was placed in a stereotaxic device and lubricant
applied to the eyes. An incision was made over the skull
and the surface exposed. A 24 gauge guide cannula was
implanted bilaterally into the ACC. Dental cement was
used to keep the cannula in place and sterile silk sutures
were used to close the skin. Mice were injected with
1.0 ml sterile saline (i.p.) for hydration. Animals were
allowed to recover in a chamber containing a recirculat-
ing water blanket until their righting reflex returned;
they were then placed in a clean cage and given mois-
tened food. Ketoprofen (0.5 mg/ml) was given intrao-
peratively as an analgesic. The animal was given at least
one week to fully recover. For microinjection, a 30
gauge injection cannula, which is 0.8 mm lower than
the guide, were used for drug infusion, 0.5 ul delivered
over 90 sec. Behavioral responses were measured
20 min after microinjection.
Primary cortical neuron culture
Cortical neurons were prepared from postnatal day 0
(P0) mice using methods as described previously [26,27].
The cortices were dissected, minced, and trypsinized for
15 min using 0.125% trypsin (Invitrogen, CA). Cultures
were grown in Neurobasal-A medium supplemented
w i t hB 2 7a n d2m MG l u t a M a x( I n v i t r o g e n ,C A )a n d
incubated at 37°C in 95% air, 5% CO2 with 95% humid-
ity. Cultures were transfected with neurabin or control
siRNA using Transfection reagent for siRNA (Invitro-
gen, CA) at DIV 10. The expression of neurabin was
detected 40 hours later by Western blot.
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Coronal brain slices (300 μm) containing the ACC from
six- to eight-week-old male mice were prepared using
standard methods [22]. Slices were transferred to a sub-
merged recovery chamber with oxygenated (95% O2and
5% CO2) artificial cerebrospinal fluid (ACSF) containing
(in mM): 124 NaCl, 2.5 KCl, 2 CaCl2,2M g S O 4,2 5
NaHCO3,1N a H 2PO4, 10 glucose at room temperature
for at least 1 hour.
All electrophysiological experiments were performed
at room temperature. An Olympus BX51WI microscope
(Tokyo, Japan) with infrared DIC optics was used for
visualization of whole-cell patch clamp recording. Exci-
tatory postsynaptic currents (EPSCs) were recorded
from layer II/III neurons with an Axon 200 B amplifier
(Molecular devices, CA) and the stimulations were deliv-
ered by a bipolar tungsten stimulating electrode placed
in layer V of the ACC slices. EPSCs were induced by
repetitive stimulations (duration is 200 μs, intensity is
adjusted to induce EPSCs with amplitude of 50-100 pA
at 0.05 Hz and neurons were voltage clamped at
-70 mV. The recording pipettes (3-5 MΩ) were filled
with solution containing (mM): 120 K-gluconate,
5N a C l ,1M g C l 2, 0.2 EGTA, 10 HEPES, 2 Mg-ATP, 0.1
Na3-GTP and 10 phosphocreatine disodium salt
(adjusted to pH 7.2 with KOH). Picrotoxin (100 μM)
w a sa l w a y sp r e s e n tt ob l o c kG A B A Areceptor-mediated
inhibitory currents and monitored throughout the
synaptic currents. In the mEPSC and mIPSC experi-
ments, 1 μM TTX were perfused into the ACSF to
blocking the activities of sodium currents. Access resis-
tance was 15-30 MΩ a n dw a sm o n i t o r e dt h r o u g h o u t
the experiment. Data were discarded if access resistance
changed more than 15% during an experiment.
siRNA preparation and microinjection
Stealth neurabin-targeted siRNA or siRNA negative con-
trol (Invitrogen, CA) and Invivofectamine Reagent (Invi-
trogen, CA) were gently mixed together then incubated
for 30 min at room temperature in an orbital shaker. 5%
glucose was added, and the mixture was transferred into
an Amicon Ultra-4 Centrifugal Filter Device (Ultracel -
100 k; Millipore, MA) and centrifuged for 1 hour.
Mice were anesthetized with i.p. injection of a mixture
of xylazine (10 mg/kg) and ketamine (130 mg/kg). A 30
gauge needle was lowered into the ACC (AP 0.7 mm;
ML 0.3 mm; VD 1.75 mm) and the prepared siRNA was
injected. Mice were injected with 1.0 ml sterile saline
(i.p.) for hydration. Ketoprofen (0.5 mg/ml) was given
intraoperatively as an analgesic.
Data analysis
Statistical comparisons were made using the Student’s
t-test or two way ANOVA to identify significant
differences. All data are expressed as mean value ± stan-
dard error of the mean. In all cases, p < 0.05 was con-
sidered statistically significant.
Results
The ACC is critical for anxiety- and depression-like
behaviors
To determine the role of the ACC in anxiety, we micro-
injected muscimol, a potent, selective GABAA receptor
agonist, into the ACC of C57BL/6 mice, then tested
them on the elevated plus maze. Muscimol-injected
mice spent significantly more time (Figure 1C; n = 9 for
muscimol, n = 6 for saline, * p < 0.05) and made more
entries into the open arms (Figure 1D) of the elevated
plus maze than the saline-injected mice, suggesting that
the ACC was critical for anxiety-like behaviors. There
were no differences between groups for closed arm
entries (Figure 1D), indicating that the phenotypic dif-
ferences were not due to hyperactivity. Next, we micro-
injected into the ACC midazolam, a short-acting
benzodiazepine that has potent anxiolytic properties.
Similarly to mice microinjected with muscimol, midazo-
lam-injected mice spent significantly more time in the
open arms of the elevated plus maze than the saline-
injected mice (Figure 2A; n = 6 for midazolam, n = 7
for saline, * p < 0.05), suggesting that injecting a clini-
cally used benzodiazepine into the ACC was sufficient
enough to reduce anxiety-like behavior. There were no
differences between groups for closed arm entries
(Figure 2B). Additionally, since anxiety and depression
are often comorbid in patients, we tested for depres-
sion-related behavior, as measured by the forced swim
test. The forced swim test paradigm reflects the beha-
vioral response to inescapable stress, not conflict, and is
sensitive to antidepressant but not anxiolytic treatments
[28,29]. Rodents usually struggle to escape from these
situations, interspersed with periods of immobility that
has been interpreted as “behavioral despair” [30]. When
we used the forced swim test to assess mice microin-
jected with muscimol, we found decreased immobility
when compared to the controls (Figure 1E; n = 8 for
muscimol, n = 6 for saline, * p < 0.05). The data suggest
that the ACC is critical for both anxiety- and depres-
sion-like behaviors.
Neurabin modulates anxiety-like behavior of the elevated
plus maze
Neurabin is a synaptic protein found in both presynaptic
terminals and dendritic spines of neurons in the pre-
frontal cortex [7]. Since neurabin has previously been
found to contribute to the regulation of glutamate
AMPA receptor functions and its related plasticity in
the hippocampus [12], and antagonism of AMPA recep-
tors have been found to produce anxiolytic-like effects
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affect anxiety-like behavior. To that end, we examined
neurabin knockout (KO) mice in several anxiety para-
digms: elevated plus maze, open field, and light/dark
test. Neurabin KO mice made significantly more entries
i n t ot h eo p e na r m sa n ds p e n tm o r et i m ei nt h eo p e n
arms of the elevated plus maze than the wildtype mice
(Figures 3C and 3D; n = 12 for neurabin KO, n = 6 for
neurabin WT, * p < 0.05), suggesting that absence of
neurabin reduced anxiety-like behaviors. Figure 3A
shows sample traces of neurabin KO and WT mice on
the elevated plus maze. As well, closed arm entries were
comparable between genotypes (Figure 3B), indicating
that the increased activity of the neurabin KO mice in
the open arms was not due to hyperactivity. When we
examined the behavior of neurabin KO mice in two
other conflict paradigms, the open field and the light/
dark test, we found that exploration of the centre of the
open field (as a percentage of total exploratory activity)
(Figures 3F and 3G; n = 8 for neurabin KO, n = 8 for
WT) as well as the percentage of total time spent in the
light compartment during the light/dark test (Figure 3E;
n=1 0f o rn e u r a b i nK O ,n=6f o rW T )w e r ec o m p a r -
able between genotypes. These results were somewhat
s u r p r i s i n gg i v e nt h a tt h eo p e nf i e l da n dl i g h t / d a r kt e s t
are also tests of conflict between a rodent’st e n d e n c i e s
versus aversive properties [31]. Therefore, to determine
if neurabin KO mice are particularly insensitive to the
Figure 1 The ACC is critical for anxiety- and depression-like behaviors. A, Model showing the cannulation and microinjection into the ACC.
B, Diagram showing the timeline of experiment. C, Percent of time in the open arms of the elevated plus maze. D, Number of entries into the
open and closed arms of the elevated plus maze. E, Percent of active mobility in the forced swim test. F, Microinjection sites in the ACC.
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task. The apparatus (Figure 4A) consisted of a rectangu-
lar Plexiglas floor equally divided into opaque and clear
compartments, with the opaque compartment sur-
rounded on three sides by high walls and resting on an
elevated platform. The clear compartment was not
enclosed and extended out from the platform, sus-
pended over the floor so that the high elevation was
starkly apparent. The latency to cross from the dark to
the clear compartment, as well as the time spent in the
clear compartment were recorded. While the latency to
cross did not differ between genotypes (Figure 4B),
neurabin KO mice spent significantly more time in the
clear compartment than the WT mice (Figure 4C; n = 5
for neurabin KO, n = 5 for WT, * p < 0.05). In order to
ensure neurabin KO mice did not have problems with
visual acuity and depth perception, we examined the
mice on the visual cliff test, as it measures gross visual
ability [32,33]. We found that the “positive” safe
responses remained comparable between groups (71.67
± 4.77% for neurabin KO, 70.00 ± 8.37% for neurabin
WT; n = 6 for KO, n = 5 for WT). Therefore, the data
suggest that absence of neurabin could result in reduced
sensitivity to the effects of elevation.
Injecting neurabin siRNA into the ACC reduced anxiety-
like behavior
It is difficult to determine the precise regions of the
brain that contribute to anxiety in neurabin KO mice
since the gene is deleted globally. Furthermore, potential
developmental defects or compensatory changes cannot
be ruled out. Therefore, using focal application of neur-
abin siRNA, we investigated whether the inhibition of
neurabin expression in the ACC would modulate anxi-
ety-like behavior. First, to confirm the effectiveness of
the siRNA, primary cortical neuron culture at DIV 10
was transfected with siRNA negative control or neurabin
siRNA (Invitrogen, CA). The expression of neurabin was
then measured by Western blot at 48 h after transfec-
tion. We found that neurabin siRNA reduced the rela-
tive neurabin levels by approximately 70% (Figure 5A).
We also saw reduction in neurabin levels when mice
were given injections of neurabin siRNA into the ACC
for 3 consecutive days (data not shown).
Figure 2 Microinjection of a clinically used benzodiazepine into the ACC reduced anxiety-like behavior. A, Percent of time in the open
arms of the elevated plus maze. B, Number of entries into the open and closed arms of the elevated plus maze. C, Microinjection sites in the
ACC.
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ally injected into the ACC of C57BL/6 mice using Invi-
vofectamine (Invitrogen, CA), a lipid-based transfection
reagent. Second or third day following surgery, the mice
were tested on the elevated plus maze. While closed
arm entries were comparable between groups (Figure
6D), we found that the mice injected with neurabin
siRNA made significantly more entries into the open
arms and spent more time in the open arms of the ele-
vated plus maze than the siRNA negative control-
Figure 3 Neurabin modulates anxiety-like behavior of the elevated plus maze. A, Sample traces in the elevated plus maze. B, Number of
entries into the closed arms of the elevated plus maze. C, Number of open arm entries. D, Percent of time in the open arms. E, Percent of time
in the light box of the light/dark test. F, Sample traces in the open field. G,Percent path length in the centre of the open field.
Figure 4 Neurabin KO mice in the elevated emergence task. A, Model of the elevated emergence task. B, Latency to cross in the elevated
emergence task. C, Percent of time spent in the clear compartment of the elevated emergence task.
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siRNA, n = 6 for siRNA negative control, * p < 0.05),
suggesting that reduction of neurabin in the ACC was
sufficient enough to modulate anxiety-like behaviors.
When we used the forced swim test to assess neurabin
KO mice, we found increased immobility when com-
pared to the WT mice (Figure 6F; n = 9 for neurabin
KO, n = 9 for neurabin WT, * p < 0.05), indicating that
the loss of neurabin may have increased behavioral des-
pair. Interestingly, when neurabin siRNA was injected
into the ACC, there were no significant differences in
the forced swim test between groups (Figure 6E; n = 10
for neurabin siRNA, n = 7 for siRNA negative control).
These findings demonstrate that neurabin in the ACC
may not be required to modulate depression-related
behavior.
Deletion of neurabin increased the presynaptic
transmitter release and neuronal excitability in the ACC
Finally, we wanted to investigate the potential roles of
neurabin in the excitatory transmission within the ACC.
We found that PPF was significantly reduced in neura-
bin KO mice when compared to the WT mice (Figures
7A and 7B), suggesting that presynaptic glutamate
release was increased in the ACC in neurabin KO mice.
Similar results were found in the ACC of mice injected
with neurabin siRNA (Figures 8A and 8B). To determine
whether the basic synaptic transmission was affected by
the absence of neurabin, we further examined the
mEPSC in the ACC neurons of neurabin KO and WT
mice. Neither the amplitudes nor the frequency of
mEPSC (Figures 7C-E) changed between genotypes,
indicating that neurabin may contribute to the evoked
synaptic responses in the ACC.
Discussion
Numerous human brain imaging studies have implicated
the ACC, an area long known to be engaged in both
cognitive and emotional processing [34,35], in affective
disorders [4-6]. However, lesion studies have not
reflected the brain imaging data [36]. Additionally, few
animal studies have examined the role of the ACC in
affective disorders, and similar to the human studies,
produced conflicting results [37]. Therefore, the exact
role of the ACC in affective disorders still remains to be
determined.
The present findings are the first, to our knowledge, to
show the importance of neurabin in anxiety- and depres-
sion-related behaviors. We found that neurabin KO mice
showed reduced anxiety-like behaviors in the elevated
plus maze. However, when tested on two other conflict
paradigms, the open field and the light/dark test, the
results remained comparable between genotypes, sug-
gesting that neurabin selectively modulates the anxiety-
like behaviors of the elevated plus maze. Next, neurabin-
targeted siRNA was injected into the ACC to see if anxi-
ety-like behavior would still be affected without the com-
plete absence of neurabin. Two to three days following
injection, the mice were tested on the elevated plus maze,
and similarly to neurabin KO mice, also had reduction in
anxiety-like behavior, indicating that reducing the level of
neurabin in the ACC was sufficient enough for the mod-
ulation of anxiety-like behaviors.
As anxiety and depression are often comorbid, forced
swim test was used to assess the depression-related beha-
vior of neurabin KO mice. Compared to the WT, neura-
bin KO mice had increased immobility, suggesting that
neurabin KO mice have increased behavioral despair.
The result is somewhat surprising, as anxiety and depres-
sion have been suggested to share similar genetic vulner-
abilities [38,39] and neuropharmacology, supported by
findings that SSRIs are effective treatments for both
depression and a number of anxiety disorders [40]. That
neurabin appears to act in opposing fashion in anxiety-
and depression-related behaviors does not negate this
theory, as neurabin is critical for the modulation of both,
since the absence of neurabin alters the anxiety- and
depression-related behaviors. However, neurabin clearly
affects both behaviors in different ways, possibly through
different neurocircuitries that are specific for anxiety or
depression. Interestingly, when neurabin-targeted siRNA
was injected into the ACC, there were no significant dif-
ferences in depression-like behavior between groups, sug-
gesting that neurabin in the ACC may not be required to
Figure 5 Neurabin siRNA in primary cortical neuron culture. A,
Reduction of relative neurabin levels in primary cortical neuron
culture by neurabin siRNA.
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Page 7 of 10Figure 6 Microinjectin of neurabin siRNA into the ACC reduced anxiety-like behavior. A, Injection sites in the ACC. B, Number of entries
into the open arms of the elevated plus maze. C, Percent of time in the open arms. D, Number of closed arm entries. F, Percent of active
mobility in the forced swim test. G, Percent of active mobility in the forced swim test in neurabin KO and WT mice.
Figure 7 Deletion of neurabin increased the presynaptic transmitter release and neuron excitability in the ACC. A, Sample PPF traces
from neurabin KO and WT mice. B, Neurabin KO and WT PPF of AMPAR-mediated currents. C, Sample mEPSC recordings from neurabin KO and
WT mice. D, Amplitude of mEPSCs. E, Frequency of mEPSCs.
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ety-related behavior was still reduced by a partial loss of
neurabin. This lends support to the idea that neurabin
modulates anxiety and depression, but through different
neurocircuitries that is specific for one behavior or other.
It may also be possible that the reduction in PP1 levels
observed by Allen et al. [10] in neurabin KO mice could
be absent in mice injected with neurabin-targeted siRNA,
and that it may be PP1 activity which is critical for
depression-like behavior.
We have also shown that the ACC is indeed critical
for anxiety- and depression-like behaviors in mice.
Using microinjections of mus c i m o l ,ap o t e n t ,s e l e c t i v e
GABAA receptor agonist, we found that in adult mice,
the ACC is critical for anxiety-like behaviors. Mice that
had been given microinjections of muscimol into the
ACC had reduced anxiety-like behaviors when com-
pared to the mice injected with saline. As well, microin-
jections of midazolam, a short-acting benzodiazepine,
produced similar results, indicating that application of a
clinically used anxiolytic into the ACC was sufficient
enough to reduce anxiety-like behavior. Additionally,
muscimol-injected mice also had reduced depression-
like behavior on the forced swim test. However, the
closed arm entries and total arm entries remained com-
parable to controls, suggesting that the phenotypic dif-
ferences weren’t due to hyperactivity. The data,
therefore, suggest that the ACC is critical for anxiety-
and depression-like behaviors. The work by Bissiere et
al. [37], which found that the rostral ACC does not
appear to modulate the anxiety-related behavior of rats,
doesn’t necessarily contradict this current study. As
noted by the authors, the area lesioned had selective
ipsilateral projections to and from the basolateral amyg-
dala, which previous studies have shown isn’tr e q u i r e d
for the elevated plus maze [41,42]. Additionally, the data
from Bissiere et al. show relatively high baseline anxiety,
indicating that a possible floor effect may mask potential
anxiogenic effects in the elevated plus maze [37].
Furthermore, lesions affect neurons, passing nerve fibers
and local glial cells in a non-selective manner, which
could have affected the findings.
Our data suggests that neurabin in the ACC is critical
for the modulation of the anxiety-like behavior (particu-
larly with respect to elevation) but not depression-like
behavior. However, we cannot discount the fact that the
elevated plus maze and the elevated emergence task also
contain aversive open spaces, even more so than the
open field, which is enclosed in a sound-attenuating
chamber. Additional tests will need to be devised and
conducted to test solely for elevation, and to further
determine the downstream effectors of neurabin and
their role in affective disorders. In sum, our findings of
the requirement of neurabin in anxiety-like behaviors
provide a potential novel molecular target for designing
new drug treatments for anxiety disorders.
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